The Involvement of the Hypothalamic-pituitary-gonadal, Hypothalamic-pituitary-adrenal and Somatotrophic Axes in the Development and Treatment of Schizophrenia

References (91)

1. 1 Effects of stress throughout the lifespan on the brain, behaviour and cognition [DOI]
2. 2 The Neuroendocrinology of Stress and Aging: The Glucocorticoid Cascade Hypothesis [DOI]
3. 3 Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders [DOI]
4. 4 The neurodevelopmental model of schizophrenia: update 2005 [DOI]
5. 5 Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat.
6. 6 Neurodevelopmental model of schizophrenia: update 2012 [DOI]
7. 7 Stress, the Aging Brain, and the Mechanisms of Neuron Death
8. 8 Gender differences in schizophrenia [DOI]
9. 9 Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders [DOI]
10. 10 Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. [DOI]
11. 11 Review: Chromatin Structural Features and Targets That Regulate Transcription [DOI]
12. 12 The Genetics of Schizophrenia [DOI]
13. 13 Stress and neurodevelopmental processes in the emergence of psychosis [DOI]
14. 14 Estrogen — a potential treatment for schizophrenia [DOI]
15. 15 Evidence of basal pituitary–adrenal overactivity in first episode, drug naïve patients with schizophrenia [DOI]
16. 16 Insulin and Insulin-Like Growth Factor-1 Abnormalities in Antipsychotic-Naive Schizophrenia [DOI]
17. 17 Successful Long-Term Treatment of Refractory Cushing’s Disease with High-Dose Mifepristone (RU 486) [DOI]
18. 18 Developmental changes in cortisol secretion in normal and at-risk youth [DOI]
19. 19 The associations among hippocampal volume, cortisol reactivity, and memory performance in healthy young men [DOI]
20. 20 Stress abnormalities in individuals at risk for psychosis: A review of studies in subjects with familial risk or with “at risk” mental state [DOI]
21. 21 Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia [DOI]
22. 22 Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder [DOI]
23. 23 Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia [DOI]
24. 24 Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia [DOI]
25. 25 The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: An autoradiography study [DOI]
26. 26 Interventions for the prevention and treatment of postpartum psychosis: a systematic review [DOI]
27. 27 Increased Levels of Nitric Oxide, Cortisol and Adrenomedullin in Patients with Chronic Schizophrenia [DOI]
28. 28 Negative Correlation between Negative Symptoms of Schizophrenia and Testosterone Levels [DOI]
29. 29 Estrogens and men with schizophrenia: Is there a case for adjunctive therapy? [DOI]
30. 30 Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia [DOI]
31. 31 Role of Estrogen Treatment in the Management of Schizophrenia [DOI]
32. 32 The Role of Oestrogen and Other Hormones in the Pathophysiology and Treatment of Schizophrenia [DOI]
33. 33 Testosterone in Newly Diagnosed, Antipsychotic-Naive Men With Nonaffective Psychosis [DOI]
34. 34 Psychoendocrinology of Ego Disintegration [DOI]
35. 35 Further evidence for a specific role of estradiol in schizophrenia? [DOI]
36. 36 Prenatal Development of Glucocorticoid Receptor Gene Expression and Immunoreactivity in the Rat Brain and Pituitary Gland: A Combined in situ Hybridization and Immunocytochemical Analysis [DOI]
37. 37 Glucocorticoid antagonists in neuropsychotic disorders [DOI]
38. 38 Short-Term Testosterone Augmentation in Male Schizophrenics [DOI]
39. 39 Pituitary volume and early treatment response in drug-naïve first-episode psychosis patients [DOI]
40. 40 Permanent and plastic epigenesis in neuroendocrine systems [DOI]
41. 41 The hormonal environment in utero as a potential aetiological agent for schizophrenia [DOI]
42. 42 Double-Blind Antiglucocorticoid Treatment in Schizophrenia and Schizoaffective Disorder: A Pilot Study [DOI]
43. 43 Hypothesis: Do insulin-like growth factors underlie associations of birth complications, fetal and pre-adult growth with schizophrenia? [DOI]
44. 44 IGF1, growth pathway polymorphisms and schizophrenia: A pooling study [DOI]
45. 45 Urinary Estrogen Metabolites and Breast Cancer: A Combined Analysis of Individual Level Data [DOI]
46. 46 TESTOSTERONE IN NEWLY DIAGNOSED, ANTIPSYCHOTIC-NAïVE MEN WITH NONAFFECTIVE PSYCHOSIS: A TEST OF THE ACCELERATED AGING HYPOTHESIS [DOI]
47. 47 Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis.
48. 48 Prediction of response to haloperidol in schizophrenia [DOI]
49. 49 Schizophrenia and Cushing's syndrome cured by adrenalectomy [DOI]
50. 50 Psychosis, Cushing's syndrome and hyperparathyroidism.
51. 51 Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse [DOI]
52. 52 Epigenetic reprogramming in mammals [DOI]
53. 53 Neuroprotection by estradiol [DOI]
54. 54 Intra-individual Change Over Time in DNA Methylation With Familial Clustering [DOI]
55. 55 The Stress Cascade and Schizophrenia: Etiology and Onset [DOI]
56. 56 The Role of Estrogens in Schizophrenia Gender Differences [DOI]
57. 57 Stress Effects on Morphology and Function of the Hippocampusa [DOI]
58. 58 Experience-Dependent Epigenetic Modifications in the Central Nervous System [DOI]
59. 59 Glucocorticoids, developmental ‘programming’ and the risk of affective dysfunction [DOI]
60. 60 Fetal origins of insulin resistance and obesity [DOI]
61. 61 Glucocorticoid Hormones and Early Brain Development in Schizophrenia [DOI]
62. 62 Pituitary volume in psychosis [DOI]
63. 63 Perinatal programming of adult hippocampal structure and function; emerging roles of stress, nutrition and epigenetics [DOI]
64. 64 Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia [DOI]
65. 65 Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia [DOI]
66. 66 Prolonged Salivary Cortisol Recovery in Second-Trimester Pregnant Women and Attenuated Salivary α-Amylase Responses to Psychosocial Stress in Human Pregnancy [DOI]
67. 67 Identification of Subgroups of Schizophrenia Patients With Changes in Either Immune or Growth Factor and Hormonal Pathways [DOI]
68. 68 Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial [DOI]
69. 69 Short-term estradiol treatment enhances pituitary-adrenal axis and sympathetic responses to psychosocial stress in healthy young men. [DOI]
70. 70 Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia [DOI]
71. 71 Steroids‐Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders [DOI]
72. 72 Corticosteroids: Sculptors of the Hippocampal Formation [DOI]
73. 73 Successful Long-Term Treatment of Refractory Cushing's Disease with High-Dose Mifepristone (RU 486) [DOI]
74. 74 Schizophrenia: Reproductive Hormones and the Brain [DOI]
75. 75 Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis [DOI]
76. 76 Effect of antipsychotic treatment on Insulin-like Growth Factor-1 and cortisol in schizophrenia: A longitudinal study [DOI]
77. 77 Environmental epigenetics: a role in endocrine disease? [DOI]
78. 78 Pituitary volume in unaffected relatives of patients with schizophrenia and bipolar disorder [DOI]
79. 79 Why schizophrenia genetics needs epigenetics: a review.
80. 80 Why schizophrenia genetics needs epigenetics: a review.
81. 81 The Validity of the DSM-IV Diagnostic Classification System of Non-Affective Psychoses [DOI]
82. 82 Gender and Schizophrenia: An Introduction and Synthesis of Findings [DOI]
83. 83 Short-term estradiol treatment enhances pituitary-adrenal axis and sympathetic responses to psychosocial stress in healthy young men [DOI]
84. 84 Main risk factors for schizophrenia: increased familial loading and pre- and peri-natal complications antagonize the protective effect of oestrogen in women [DOI]
85. 85 Neuroendocrine markers of high risk for psychosis: salivary testosterone in adolescent boys with prodromal symptoms [DOI]
86. 86 Increased pituitary volume in schizophrenia spectrum disorders [DOI]
87. 87 Estrogen Therapy and Noncognitive Psychiatric Signs and Symptoms in Elderly Patients With Dementia [DOI]
88. 88 Do insulin-like growth factors underlie associations of birth complications, fetal and pre-adult growth with schizophrenia? [DOI]
89. 89 The evaluation of women with schizophrenia.
90. 90 Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia [DOI]
91. 91 Human Endocrinology [DOI]

Cited by 0

No indexed citations yet.

Related research

• Low Prevalence of Metabolic Syndrome in a Group of Patients with Chronic Psychotic Disorders Taking Antipsychotic Polypharmacy in Residential Treatment While Adhering to a Mediterranean Diet — shares topic coverage
• Clinical Motivation Experience Practicum at Rehabilitation Center, Boston: A Case Study — shares topic coverage
• Review of the Challenges Facing Management of Patients with Psychotic Disorder and the Need for Mental Health Policies in Nigeria — shares topic coverage
• Perceived Barriers to Help Seeking for Psychosis among Secondary School Students in Lagos, Nigeria — shares topic coverage
• Periodic Catatonia after Thyroid Cancer — shares topic coverage